Treatment of thrombotic microangiopathy associated with systemic lupus erythematosus with low-dose rituximab as an induction agent and belimumab as a maintenance agent

Related articles

1. Application of rituximab to treat minimal change disease with refractory nephrotic syndrome in the remission maintenance phase with long-term follow-up

   This article has 6 authors:

   1. Li Tian
   2. Lingling Xing
   3. Liying Wen
   4. Ranjie Fu
   5. Xuzhi Liang
   6. Shaomei Li

2. Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyurea

   This article has 18 authors:

   1. Francesca Palandri
   2. Massimo Breccia
   3. Elena Elli
   4. Roberto LATAGLIATA
   5. Giulia Benevolo
   6. Erika Morsia
   7. Mario Tiribelli
   8. Francesco Cavazzini
   9. Alessandra D'Addio
   10. Alessia Tieghi
   11. Mirko Farina
   12. Fabrizio Cavalca
   13. Alessandra Dedola
   14. Florian Heidel
   15. Giuseppe Alberto Palumbo
   16. Elena Rossi
   17. Filippo Branzanti
   18. Valerio De Stefano

3. Benralizumab for acute thromboembolism in hypereosinophilic syndrome: A case report

   This article has 15 authors:

   1. Daiki Nagira
   2. Satoshi Miyamoto
   3. Taishiro Mizukoshi
   4. Atsushi Yanagisawa
   5. Atsushi Funauchi
   6. Kensuke Kanaoka
   7. Hanako Yoshimura
   8. Tatsunori Jo
   9. Masayoshi Higashiguchi
   10. Yujiro Naito
   11. Takayuki Shiroyama
   12. Satoshi Tetsumoto
   13. Haruhiko Hirata
   14. Yoshito Takeda
   15. Atsushi Kumanogoh